4.3 Article

T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis

期刊

CLINICAL BREAST CANCER
卷 19, 期 6, 页码 E669-E682

出版社

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clbc.2019.05.011

关键词

BCT; Early stage; Radical resection; Radiotherapy; TNBC

类别

资金

  1. National Natural Science Foundation of China [81773102]
  2. Foundation for Clinical Medicine Science and Technology Special Project of the Jiangsu Province, China [BL2014071]

向作者/读者索取更多资源

We compared the survival outcomes of breast-conserving therapy (BCT) and mastectomy in patients with T1-2N0M0 triple-negative breast cancer (TNBC). An analysis of 14,910 patients demonstrated better overall survival and cause-specific survival in patients with BCT, suggesting that BCT could be an appropriate option for T1-2N0M0 TNBC. Further prospective studies are needed to confirm these conclusions. Background: For early-stage breast cancer, the two current mainstay treatments are breast-conserving therapy (BCT; lumpectomy followed by radiotherapy [RT] and BCT) and mastectomy. Generally, triple-negative breast cancer (TNBC) is more aggressive compared to hormone receptorepositive breast cancer. We sought to investigate the effect of BCT compared to mastectomy on overall survival (OS) and breast cancerespecific survival (BCSS) in T1-2N0M0 TNBC. Patients and Methods: A population-based retrospective analysis was performed using the Surveillance, Epidemiology, and End Results (SEER) database. Patients included in the analysis were divided into 3 groups according to surgical modality and RT: BCT, mastectomy alone, and mastectomy with RT. The survival end points were OS and BCSS, and survival analysis was performed by the Kaplan-Meier method and the log-rank test among treatment types. Results: A total of 14,910 female subjects with T1-2N0M0 TNBC diagnosed between 2010 and 2014 were included. A total of 7381 patients had BCT; 6967 had mastectomy alone, and 562 had mastectomy with RT. Patients treated with BCT had better OS (log-rank P <.05) and BCSS (log-rank P < .05) than those receiving mastectomy with or without RT. The 5-year OS was 88.6% for BCT, 83.0% for mastectomy alone, and 79.6% for mastectomy with RT. The 5-year BCSS was 94.3% for BCT, 93.3% for mastectomy alone, and 83.7% for mastectomy with RT. Conclusion: In patients with T1-2N0M0 TNBC, BCT was associated with superior OS and BCSS compared to mastectomy with or without RT. After mastectomy, there was no evidence of survival benefit of RT. (C) 2019 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据